Sun Pharma Aims for Mid-to-High Single-Digit Growth in FY26

• Sun Pharma targets mid-to-high single-digit consolidated topline growth for FY26.
• Focus areas include sustainable growth, improved return ratios, and R&D investment for innovative medicines.
• FY25 gross sales reached Rs 52,041 crore, with India contributing 33% and EBITDA at 29%.
• Maintains market leadership as India's largest pharma company with an 8.3% market share.
• Shares fell nearly 1% to Rs 1,720, extending losses for the third consecutive session.

Why It Matters: Sun Pharma projects strong FY26 growth, focusing on R&D and market leadership despite recent stock dip.